Association of fibrin monomer polymerization function, cerebrovascular risk factors and ischemic cerebrovascular disease in old people

Abstract

In order to investigate the association of fibrin monomer polymerization function (FMPF) with traditional cerebrovascular risk factors and ischemic cerebrovascular disease in old people, 1∶1 paired case-control comparative study was performed for FMPF and traditional cerebrovascular risk factors on 110 cases of old ischemic cerebrovascular disease and 110 controls matched on age, sex and living condition. The results showed that cerebrovascular risk factors were more prevalent in case group than in control group. In the case group, FMPF was significantly higher than in control group. There was a significant positive correlation between hypertension and fibrin monomer polymerization velocity (FMPV), hypertension and fibrinogen (Fbg), alcohol consumption and Fbg, but no significant correlation between diabetic mellitus, smoking and FMPF was found. Among the parameters of blood lipids, there were significant positive correlations between total cholesterol (TC) and parameters of FMPF to varying degrees, triglycerides (TG) and FMPV, TG and Fbg. Our results also showed there were significant linear trends between TC and FMPV (P<0.001), TC and Fbg (P=0.0087), TG and FMPV/Amax (maximum absorbance) (P=0.0143) respectively. Multiple logistic regression analysis revealed that FMPF in case group remained significantly higher than control group after adjustment of all risk factors that were significant in univariate analysis. It was concluded that there is a possible pathophysiological link between FMPF and cerebrovascular risk factors. An elevated FMPF is associated with ischemic cerebrovascular disease and an independent risk factor of this disease. In old people, detection of FMPF might be a useful screening to identify individuals at increased cerebrothrombotic risk.

Keywords

old people / fibrin monomer polymerization function / cerebrovascular disease / risk factor

References

[1] KoenigW. Recent progress in the clinical aspects of fibrinogen. Eur Heart J, 1995, 16(Suppl A): 54-54

[2] BotsM L, ElwoodP C, SalonenJ T, et al. . Level of fibrinogen and risk of fatal and non-fatal stroke. J Epidemiol Community Health, 2002, 56(Suppl 1): i14-i14

[3] WalzlM, LechnerH, WalzlB, et al. . Improved neurological recovery of cerebral infraction after plasmapheretic reduction of lipids and fibrinogen. Stroke, 1993, 241447-1447